XLO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

XL

Mkt Cap

$55.5M

Volume

29.47K

Next Earnings

November 12th

Loading chart

XL

XLOXilio Therapeutics, Inc. Common Stock

XLO

Pay with—

Available Balance0.00

XL

Mkt Cap

$59.4M

Volume

29.47K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xilio Therapeutics granted stock options to new employees and newly appointed Chief Medical Officer Yariv Houvras, M.D., Ph.D. on October 1, 2026. The company granted 100,895 shares to two new employees and 105,000 shares to Dr. Houvras at an exercise price of $8.91 per share, with a standard vesting schedule of 25% after one year followed by 36 monthly installments.GlobeNewswire Inc. · Oct 2, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xilio Therapeutics granted non-qualified stock options to purchase 19,865 shares to two new employees at an exercise price of $8.88 per share on September 1, 2026. The options have a ten-year term with 25% vesting on the first anniversary and the remaining 75% vesting monthly over three years, subject to continued employment.GlobeNewswire Inc. · Sep 2, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xilio Therapeutics granted non-qualified stock options to purchase 3,257 shares to two new employees at an exercise price of $8.48 per share on April 1, 2026. The options have a ten-year term with a 25% vesting on the first anniversary and remaining 75% vesting monthly over three years, subject to continued employment.GlobeNewswire Inc. · Apr 3, 2026

Xilio Therapeutics Announces Pricing of Underwritten OfferingXilio Therapeutics announced the pricing of an underwritten offering of 74.78 million pre-funded warrants at $0.5349 per warrant, expected to raise approximately $40 million in gross proceeds. The financing was led by existing investor Coastlands Capital and included participation from Gilead Sciences, OrbiMed, and Perceptive Advisors. Proceeds will be used to advance product development and for general corporate purposes.GlobeNewswire Inc. · Feb 12, 2026

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingXilio Therapeutics will present clinical and preclinical data on tumor-activated immuno-oncology therapies at the Society for Immunotherapy of Cancer's annual meeting in November 2025, highlighting research on vilastobart, efarindodekin alfa, and masked T cell engager programs.GlobeNewswire Inc. · Oct 3, 2025

Xilio Therapeutics Announces Closing of $50.0 Million Public OfferingXilio Therapeutics announced the closing of a $50.0 million public offering, with the potential for up to $150.0 million in total gross proceeds if all warrants are exercised. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences, and included participation from Gilead Sciences, Logos Capital, and Samsara BioCapital.GlobeNewswire Inc. · Jun 5, 2025

Xilio Therapeutics Announces Proposed Public OfferingXilio Therapeutics, a clinical-stage biotechnology company, announced a proposed public offering of pre-funded warrants, Series A, B, and C warrants to purchase shares of common stock. The company plans to use the net proceeds to advance the development of its product candidates and for general corporate purposes.Benzinga · Jun 2, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerXilio Therapeutics announced updated Phase 2 data for its tumor-activated anti-CTLA-4 drug vilastobart in combination with atezolizumab, showing a 26% preliminary objective response rate in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer without liver metastases.GlobeNewswire Inc. · May 31, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsXilio Therapeutics reported progress in its pipeline, including positive initial Phase 2 data for its tumor-activated anti-CTLA-4 therapy vilastobart in metastatic microsatellite stable colorectal cancer. The company also announced a collaboration with AbbVie to develop novel tumor-activated immunotherapies.GlobeNewswire Inc. · Mar 11, 2025

RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.GlobeNewswire Inc. · Feb 10, 2025

to start trading

XL

XLOXilio Therapeutics, Inc. Common Stock

XLO

Pay with—

Available Balance0.00

Your PositionYou don't own any XLO yet.

Related Tickers

Earnings